Business

Licensing-in/Collaboration

Hanmi Pharm is dedicated to developing and providing innovative, valuable drugs to its customers. In order to pursue this goal, Hanmi is seeking out various types of collaborative opportunities, including product & pipeline in-licensing, research/development collaboration, co-promotion/co-marketing with domestic and overseas research institutes, pharmaceutical companies and biotech companies and so on.

We Value our R&D

Sustained Growth during COVID-19 Pandemic
  • Hanmi is among the top 5 Korean pharmaceutical companies, with market cap of $8.18B & revenue of $1.74B (2020)
Strong focus on R&D (+580 experts; 25% R&D Staffs)
  • Innovative pipeline expands & late stage clinical studies and registration
  • 6 R&D centers in Korea & China
  • Unique Platform

    LAPSCOVERYTM (Long Acting Protein / Peptide Discovery Platform Technology)

    ORASCOVERYTM (Oral Drug Discovery Platform Technology)

    PENTAMBODYTM (Penta amino acid mutated bispecific antibody)

Advances in R&D (Average 19% of Revenue)
  • Strong commitment in R&D supported by investment
  • Multi-angle approaches powered by strong internal R&D capacity, as well as open innovation
  • COVID19: Developing full-cycle lineup from prophylactic vaccine to diagnosis and therapeutics
  • Pipeline
Efforts to overcome COVID-19 : Manufacturing & Development Capabilities Against Pandemic
  • cGMP Production Facilities with on-site R&D resources
  • Hanmi Bio Plant : Biologics Manufacturing and Development (mRNA/DNA/Protein)
  • Hanmi Fine Chemicals : Synthetic Chemical APIs, Nucleotide, Intermediates, Peptides

BioplantBiologics

Hanmi Bio Plant

  • RNA/DNA
  • Protein

Fine ChemicalAPIs

Hanmi Fine Chemical

  • Nucleotide
  • Peptide
  • PEG
Strategic Properties in R&D

Focusing on Core Therapeutic Areas“Creating value through innovation”

  • Inflammation & Fibrosis

    • Extensive research on human incretin analogues to treat inflammatory and fibrotic disease
    • Co-agonists to resolute NASH, a complex disease with no approved therapies

  • Metabolic Disease

    • Extensive research on human incretin analogues to treat inflammatory and fibrotic disease
    • Novel solutions for OBESITY and T2DM together with mono and combination regimens

  • Oncology/Immuno-Oncology

    • Cancer treatment through innovative platforms, TKIs, Biologics and Immuno-oncologics

  • Rare Disease

    • Technologies to overcome rare disease.
      • Nucleotide
      • Peptide
      • PEG

  • Innovative Platform Technology

    • New modality (RNA-based therapy, Drug delivery system), COVID-19, PROTAC, AI-based platform to bring therapeutic effect
Inflammation & Fibrosis Metabolic Disease Oncology/Immuno-Oncology Rare Disease Innovative Platform Technology
Extensive research on human incretin analogues to treat inflammatory and fibrotic disease Cancer treatment through innovative platforms, TKIs, Biologics and Immuno-oncologics Technologies to overcome rare disease.
  • Nucleotide
  • Peptide
  • PEG
 New modality (RNA-based therapy, Drug delivery system), COVID-19, PROTAC, AI-based platform to bring therapeutic effect
Co-agonists to resolute NASH, a complex disease with no approved therapies Novel solutions for OBESITY and T2DM together with mono and combination regimens